ACTG A5095 -PROTEASE INHIBITOR-SPARING REGIMENS FOR THE INITIAL TREATMENT OF HIV

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。这项研究的目的是了解每种药物组合在多大程度上降低了血液中艾滋病毒的含量，并将其保持在较低水平，以及这些药物组合的耐受性如何，以及它们是否安全。受试者必须从未服用过抗hiv药物，并且病毒载量大于400份。受试者随机分为以下治疗组：A组：ABC+3TC+ZDV联合片3TC+ZDV安慰剂片（无活性药物）EFV胶囊每日1次；B组：ABC+3TC+ZDV联合片3TC+ZDV安慰剂片EFV安慰剂胶囊；C组：ABC+3TC+ZDV安慰剂3TC+ZDV联合片EFV胶囊。这项研究持续大约3年半。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to learn how well each combination of drugs lowers the amount of HIV in the blood and keeps it low and how well the drug combinations are tolerated and if they are safe. Subjects must be never have taken anti-HIV drugs, and have a viral load greater than 400 copies. Subjects will be randomized by chance to one of the following treatment groups: Group A: ABC+3TC+ZDV combination tablet 3TC+ZDV placebo tablet (no active drug) EFV capsules once daily; Group B: ABC+3TC+ZDV combination tablet 3TC+ZDV placebo tablet EFV placebo capsules; Group C: ABC+3TC+ZDV placebo 3TC+ZDV combination tablet EFV capsules. This study lasts about 3.5 years.